SWAV Shockwave Medical

Shockwave Medical to Participate in Two Upcoming Investor Conferences

Shockwave Medical to Participate in Two Upcoming Investor Conferences

SANTA CLARA, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor conferences:

  • The 2022 Wells Fargo Healthcare Conference

    Fireside Chat on Thursday, September 8, 2022, at 9:45 a.m. Eastern Time.
  • The Morgan Stanley 20th Annual Global Healthcare Conference

    Fireside Chat on Tuesday, September 13, 2022, at 2:05 p.m. Eastern Time.

Interested parties may access live and archived webcasts of the events on the “Investors” section of the company’s website at: .

About Shockwave Medical, Inc.

Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit .

Media Contact:

Scott Shadiow

+1.317.432.9210

Investor Contact:

Debbie Kaster

 



EN
26/08/2022

Underlying

SWAVShockwave Medical

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shockwave Medical

 PRESS RELEASE
Free
SWAV Shockwave Medic...

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said...

May 6, 2024 1 EN
Gary Brode
  • Gary Brode
SWAV SHOCKWAVE MEDICAL
04/25/24 April 25, 2024 1 EN
 PRESS RELEASE
Free
SWAV Shockwave Medic...

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-W...

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three...

April 8, 2024 1 EN
Gary Brode
  • Gary Brode
JNJ JOHNSON & JOHNSON
SWAV SHOCKWAVE MEDICAL
04/06/24 April 6, 2024 1 EN
Gary Brode
  • Gary Brode
SWAV SHOCKWAVE MEDICAL
03/26/24 March 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch